Usfda Issues Warning Letter To Cipla For Goa Manufacturing Facility
Drug Firm Cipla Ltd On Wednesday Said That The Us Health Regulator Has Issued A Warning Letter To The Company For Its Manufacturing Facility In Goa."Further To Our Earlier Communication On The Goa Manufacturing Facility Inspection Conducted From September 16-27, 2019 By The United States Food And Drug Administration (Usfda), The Company Has Received A Warning Letter From Usfda," Cipla Ltd Said In A Regulatory Filing.The Company Further Said That It Remains Committed To Maintain Highest Standards Of Compliance And Will Work Closely With The Agency To Comprehensively Address All The Observations.Shares Of Cipla Were Trading At Rs 418.30 A Piece On Bse In The Morning Trade On Bse, Down 1.66 Per Cent From Its Previous Close.
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
